Biotricity, Inc. (BTCY) Fair Value 2026

BTCY · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.0 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (39/100)

Quick Summary — As of 2026-08-27, Biotricity, Inc. (BTCY) trades at $0.12. QOC: 6.0/10. Value Trap Risk: 39/100 (LOW). 1/13 models active.

Key Facts

Ticker
BTCY
Price
$0.12
Quality Score
6.0/10
Value Trap Risk
39/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +305.0% upside with 43% confidence
Risk: Limited model coverage (1/13) may reduce confidence

What Fair Value Does Each Model Give BTCY?

1 Intrinsic Value Models vs. Current Price ($0.12)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.49 +305.0%

All Models Active

All 1 models are displayed above.

What Is Biotricity, Inc. (BTCY) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Biotricity, Inc.. Trading at $0.12 against an estimated intrinsic value of $0.49, 1 of 1 active models flag meaningful upside of +305.0% at the median.

What Do the Models Say About BTCY?

1 of 13 models are currently active for BTCY. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does BTCY Rank in Medical Devices?

Among 157 Medical Devices stocks, BTCY ranks #92 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

Biotricity, Inc.'s positioning within the Medical Devices segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.

Is BTCY a Value Trap?

CirclFi's Value Trap algorithm assigns BTCY a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Biotricity, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Biotricity, Inc. earns a quality score of 6.0/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BTCY valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BTCY's 1 active models, average confidence is 43%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Biotricity, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

SSIISS Innovations International, Inc.QOC 6.0LABStandard BioTools Inc.QOC 5.9VYCOVycor Medical, Inc.QOC 6.0XAIRBeyond Air, Inc.QOC 5.8AIDX20/20 Biolabs, Inc.QOC 6.0OWLTOwlet, Inc.QOC 5.8RMSLREMSleep Holdings, Inc.QOC 4.6TCMDTactile Systems Technology, Inc.QOC 8.8CERSCerus CorporationQOC 6.9IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: SSII · LAB · VYCO · XAIR · AIDX · OWLT · RMSL · TCMD · CERS · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to BTCY?

7 companies across all industries closest to BTCY’s Quality of Company score of 6.0/10.

PRMPerimeter Solutions, Inc.QOC 6.0ISCOInternational Stem Cell CorporationQOC 6.0RANIRani Therapeutics Holdings, Inc.QOC 6.0SKINSkinHealth Systems Inc.QOC 6.0NUVBNuvation Bio Inc.QOC 6.0OSGOctave Specialty Group, Inc.QOC 6.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PRM · ISCO · RANI · SKIN · NUVB · OSG · NVDA

Where Does BTCY Sit in CirclFi's Medical Devices Rankings?

BTCY is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Biotricity, Inc.’s Valuation?

What is Biotricity, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Biotricity, Inc. (BTCY). The Quality of Company score is 6.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BTCY overvalued or undervalued right now?

At $0.12, 1 of 1 active models suggest BTCY may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Biotricity, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 6.0 mean for BTCY?

Biotricity, Inc.'s QOC of 6.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BTCY?

CirclFi analyzes BTCY with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is BTCY a value trap in 2026?

Biotricity, Inc.'s Value Trap score is 39/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Biotricity, Inc. (BTCY) a Quality of Company score of 6.0/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/BTCY/ · Methodology
Primary sources for this BTCY valuation
  • Financial statements: Biotricity, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001630113) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BTCY as of ; valuations recomputed .